C4 Therapeutics, Inc. (CCCC)
3.10
+0.15
(+5.08%)
USD |
NASDAQ |
Nov 06, 16:00
3.09
-0.01
(-0.32%)
After-Hours: 20:00
C4 Therapeutics Max Drawdown (5Y) : 97.82% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 97.82% |
| September 30, 2026 | 97.82% |
| August 31, 2026 | 97.82% |
| July 31, 2026 | 97.82% |
| June 30, 2026 | 97.82% |
| May 31, 2026 | 97.82% |
| April 30, 2026 | 97.82% |
| March 31, 2026 | 97.82% |
| February 28, 2026 | 97.82% |
| January 31, 2026 | 97.82% |
| December 31, 2025 | 97.82% |
| November 30, 2025 | 97.82% |
| October 31, 2025 | 97.82% |
| September 30, 2025 | 97.82% |
| August 31, 2025 | 97.82% |
| July 31, 2025 | 97.82% |
| June 30, 2025 | 97.82% |
| May 31, 2025 | 97.82% |
| April 30, 2025 | 97.82% |
| March 31, 2025 | 97.66% |
| February 28, 2025 | 97.66% |
| January 31, 2025 | 97.66% |
| December 31, 2024 | 97.66% |
| November 30, 2024 | 97.66% |
| October 31, 2024 | 97.66% |
| Date | Value |
|---|---|
| September 30, 2024 | 97.66% |
| August 31, 2024 | 97.66% |
| July 31, 2024 | 97.66% |
| June 30, 2024 | 97.66% |
| May 31, 2024 | 97.66% |
| April 30, 2024 | 97.66% |
| March 31, 2024 | 97.66% |
| February 29, 2024 | 97.66% |
| January 31, 2024 | 97.66% |
| December 31, 2023 | 97.66% |
| November 30, 2023 | 97.39% |
| October 31, 2023 | 97.27% |
| September 30, 2023 | 96.42% |
| August 31, 2023 | 94.55% |
| July 31, 2023 | 94.55% |
| June 30, 2023 | 94.55% |
| May 31, 2023 | 94.14% |
| April 30, 2023 | 94.14% |
| March 31, 2023 | 93.86% |
| February 28, 2023 | 89.98% |
| January 31, 2023 | 89.98% |
| December 31, 2022 | 89.98% |
| November 30, 2022 | 89.98% |
| October 31, 2022 | 89.98% |
| September 30, 2022 | 89.98% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Intellia Therapeutics, Inc. | 96.45% |
| Kymera Therapeutics, Inc. | 87.51% |
| NKGen Biotech, Inc. | 100.00% |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -70.14 |
| Beta (5Y) | 3.166 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 159.8% |
| Historical Sharpe Ratio (5Y) | -0.2762 |
| Historical Sortino (5Y) | -0.9894 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 35.97% |